Should I buy Bruker (BRKR) stock or is it too late?
⭐ The most reliable of them, either direction: Guggenheim — 77% of its targets hit on this sector (52 calls tested). It aims for $70 (+18 %), call made on June 30, 2026, maturing on June 30, 2027 (59 d ago).
Firm-by-firm track record on Bruker
| Firm | % right | Gain vs sector | Calls | Aims for |
|---|---|---|---|---|
| Goldman Sachs | 57 % | +10.1 % | 7 | $35 -41% |
| Wells Fargo | 50 % | +9.3 % | 8 | $55 -7% |
| UBS | 75 % | +9.2 % | 8 | $45 -24% |
| Barclays | 50 % | +4.3 % | 10 | $60 +1% |
| B of A Securities | 56 % | +3.9 % | 9 | $60 +1% |
| Citigroup | 33 % | -10.6 % | 9 | $53 -11% |
| SVB Leerink | 57 % | +9.9 % | 7 | — |
✅ Reasons to believe
- Few solid positives from analysts right now: of 7 ratings, only 4 buys, and the median price target ($60) is barely above the price (+1%, at $59). Caution prevails.
⚠️ Reasons to hesitate
- Even the most reliable firm on BRKR, UBS (75% hit rate, 8 scored calls), only targets $45 (call made on May 8, 2026, maturing on May 8, 2027) (-24%) in its most recent call, and $43 (call made on November 4, 2025, maturing on November 4, 2026) (-27%) in the one coming due soonest. The stock may already have run past its target.
- The consensus is not unanimous: of 7 ratings, 3 are neutral.
- Limited upside: the median target is only +1% from the current price.
- A 12-month target is not a guaranteed path: the price can fall in the meantime.
- Negligible dividend (0.3% yield): your return depends mostly on price appreciation.
The analyst consensus on BRKR
Median target $60 (+1%) · 7 ratings · Buy consensus
⚠️ Information, not investment advice. Past performance does not guarantee future results. Analyst targets on a ~12-month horizon.
Frequently asked questions
Should you invest in Bruker now?
We won't decide for you. The facts: 57% of analysts rate it a buy, median target $60 (+1%), and UBS (most reliable on BRKR, 75%) targets $45. Weigh that against valuation. This is not personalized advice.
Is it too late to invest in Bruker?
The stated upside is small: the median target ($60) sits just +1% from the price ($59) (most reliable on BRKR: UBS, 75%). The real question isn't "too late" but the price-to-value gap and risk. Not advice.
Is Bruker still worth investing in?
It depends on the gap between the price ($59) and its estimated value: analysts target $60 on median (+1%), with 57% buys (most reliable on BRKR: UBS, 75%). Cross-check with their real reliability on BRKR and the cautions above. Information, not advice.
What's the main risk in buying BRKR?
Even the most reliable firm on BRKR, UBS (75% hit rate, 8 scored calls), only targets $45 (call made on May 8, 2026, maturing on May 8, 2027) (-24%) in its most recent call, and $43 (call made on November 4, 2025, maturing on November 4, 2026) (-27%) in the one coming due soonest. The stock may already have run past its target.
→ Go deeper: the full Bruker profile (consensus, analyst reliability, price target, performance).